TB-500 (5 mg Vial) Dosage Protocol

TB-500 (5 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) of thymosin beta-4 that promotes systemic tissue repair by binding G-actin, driving cell migration and angiogenesis, and reducing inflammation across multiple tissue types.[1] A loading-and-maintenance structure is used to saturate tissue levels before reducing to a sustaining dose.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 5.0 mg/mL concentration.
  • Loading dose: 2.5 mg twice weekly for 4–6 weeks.
  • Easy measuring: At 5.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 50 mcg. A 2.5 mg dose = 50 units / 0.50 mL.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.
TB-500 5mg Vial

Dosing & Reconstitution Guide

Educational loading and maintenance protocol for subcutaneous TB-500 injection

Loading + Maintenance Protocol (1.0 mL = 5.0 mg/mL)

Phase Dose Units (U-100) Volume Frequency
Loading (Weeks 1–6) 2.5 mg 50 units 0.50 mL 2× weekly
Maintenance (Weeks 7+) 2.5 mg 50 units 0.50 mL 1× weekly

Each 5 mg vial at 5.0 mg/mL provides 2 loading doses (or 2 maintenance doses). A 6-week loading cycle requires 12 injections = 30 mg → 6 vials. TB-500 distributes systemically, so injection site proximity to the injury is less critical than with BPC-157.

Reconstitution Steps

  1. Allow frozen vial to reach room temperature (10–15 minutes).
  2. Draw 1.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; do not inject directly onto the lyophilised cake.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 6-week loading phase at 2.5 mg twice weekly (12 injections, 30 mg total).

  • TB-500 Vials (5 mg each): 30 mg ÷ 5 mg per vial → 6 vials.
  • Insulin Syringes (U-100, 1 mL): 12 injections → 12 syringes.
  • Bacteriostatic Water (10 mL bottles): 1.0 mL per vial → 1 × 10 mL bottle covers 10 vials.
  • Alcohol Swabs: 2 per injection → 24 swabs for the loading phase.
TB-500 5mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Goal: Systemic tissue repair via G-actin binding, cell migration facilitation, angiogenesis, anti-inflammatory, and anti-fibrotic signalling.[1]
  • Schedule: Loading 2× weekly for 4–6 weeks, then maintenance 1× weekly.
  • Dose: 2.5 mg per injection (50 units / 0.50 mL).
  • Reconstitution: 1.0 mL BAC water per 5 mg vial → 5.0 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

Dosing Protocol

  • Loading (Weeks 1–6): 2.5 mg (50 units / 0.50 mL) subcutaneous, twice weekly.[1]
  • Maintenance (Weeks 7+): 2.5 mg (50 units / 0.50 mL) subcutaneous, once weekly or once every 2 weeks.
  • Injection site: Abdomen, thigh, or upper arm; TB-500 distributes systemically from any site.
  • Duration: Assess healing progress at week 8; extend loading or begin maintenance based on response.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy or particulate.

Important Notes

  • TB-500 distributes systemically — injection proximity to injury site is not required, though abdomen or thigh are most convenient.
  • WADA-prohibited (Category S2: Non-Approved Peptide Hormones) — athletes subject to anti-doping rules must not use TB-500.
  • Most researchers combine TB-500 with BPC-157 (Wolverine Stack) for complementary local + systemic tissue repair. See the Wolverine Stack Protocol.
  • Track pain scores, range of motion, and swelling at weeks 2, 4, and 8 to assess response.

How This Works

TB-500 corresponds to amino acids 17–23 of thymosin beta-4 (Tβ4), a 43-amino acid protein constitutively expressed in platelets, macrophages, and most nucleated cells. Under injury, Tβ4 is released from activated platelets to initiate repair.[1]

TB-500 sequesters G-actin (monomeric actin), controlling the pool available for filament polymerisation and enabling rapid migration of fibroblasts, keratinocytes, and endothelial cells into wound sites. It recruits endothelial progenitor cells and upregulates VEGF signalling to drive angiogenesis, restoring blood supply to ischaemic tissue. It also down-regulates NF-κB activity and pro-inflammatory cytokines (IL-6, TNF-α) and modulates myofibroblast activity to reduce scar tissue formation — resulting in more organised, functional repair tissue.[1]

Potential Benefits & Considerations

  • Multi-tissue repair: Preclinical evidence for healing in skeletal muscle, tendons, ligaments, cardiac muscle, cornea, skin, and neural tissue.[1]
  • Angiogenesis: Tβ4 promotes endothelial progenitor cell recruitment and VEGF upregulation in ischaemia models.[2]
  • Human wound data: Phase II trial of topical Tβ4 gel improved closure of chronic venous stasis ulcers vs. standard care.[3]
  • Anti-fibrotic: Reduced scar tissue formation compared to untreated controls in multiple preclinical studies.
  • WADA status: Prohibited in- and out-of-competition for athletes under anti-doping jurisdiction.

Lifestyle Factors

  • Maintain adequate dietary protein (1.2–1.6 g/kg) to supply amino acids for tissue synthesis.
  • Gentle range-of-motion exercises during the loading phase support repair without re-injury risk.
  • Adequate sleep (7–9 hours) maximises growth hormone release and tissue anabolism during recovery.
  • Avoid NSAIDs during the active recovery phase — they can blunt prostaglandin-mediated repair signalling that TB-500 potentiates.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • Goldstein AL & Kleinman HK — Annals of the New York Academy of Sciences (2015)
    — Thymosin beta-4: a multi-functional regenerative peptide; comprehensive review of tissue repair evidence across muscle, tendon, cardiac, corneal, and neural tissue
    View Source

  • Grant DS et al. — Journal of Peptide Science (2016)
    — Thymosin beta-4 promotes endothelial progenitor cell recruitment and VEGF upregulation in ischaemia models
    View Source

  • Philp D et al. — Annals of the New York Academy of Sciences (2006)
    — Phase II wound-healing trial: Tβ4 gel significantly improved closure of chronic venous stasis ulcers vs. standard care
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source